Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer

Jun-Cheng Xuhong; Xiao-Wei Qi; Yi Zhang; Jun Jiang

Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer

Am J Cancer Res. 2019 Oct 1;9(10):2103-2119. eCollection 2019.

Authors

Jun-Cheng Xuhong¹, Xiao-Wei Qi¹, Yi Zhang¹, Jun Jiang¹

Affiliation

¹ Department of Breast and Thyroid Surgery, Southwest Hospital, Third Military Medical University Chongqing 400038, China.

PMID: 31720077
PMCID: PMC6834479

Abstract

The incidence of breast cancer ranks first among female malignant tumors that affect women's health. Epidermal growth factor receptor (EGFR) family overexpression, especially human epidermal receptor2 (HER2), features prominently in breast cancer with a significant relation to poor prognosis. Currently, specific monoclonal antibodies and tyrosine kinase inhibitors (TKIs) are the two HER2 targeting strategies that have successfully improved the prognosis of patients with HER2-positive breast cancer. This paper focuses on three officially approved TKIs for HER2 breast cancer, namely, lapatinib, neratinib and pyrotinib, and systematically reviews the mechanism, safety, efficacy and resistance of these TKIs.

Keywords: HER2-positive breast cancer; lapatinib; neratinib; pyrotinib; tyrosine kinase inhibitors.

Publication types

Review